Trends in cell therapy clinical trials 2011 – 2013

March 2, 2014

Since last year, I’m sharing some trends in cell therapy clinical trials. Real time tracking of all registered trials allows to identify trends in multiple dimensions. Today I”m posting a snapshot of trending for the last 3 years – from 2011 to 2013. There could be some minimal discrepancies in numbers between this and previous […]

Read the full article →

Role of monocytes in regenerative cell therapies

February 16, 2014

As I’ve written before, we largely don’t know what cell population underlies the mechanism of action of bone marrow or cord blood transplantation in regenerative medicine. Before infusion in neurological, cardiac, hepatic and other conditions, cord blood or bone marrow usually undergo minimal processing – red blood cells and platelet depletion. What remains before infusion […]

Read the full article →

Cell therapy clinical trials – 2013 Report

February 1, 2014

This is 2013 report of registered clinical trials in cell therapy. Every year I overview some tracked data from international clinical trials databases. You can see previous annual reports here. Definitions and criteria I tracked clinical trials which fall in definition of cell therapy: administration of living cells in human with therapeutic purpose. Besides “traditional […]

Read the full article →

Cell therapy trials failures in 2013

December 25, 2013

At the end of the year, I want to bring your attention to major failures and setbacks for cell therapy field in 2013. This is an attempt to capture the vast majority of failed clinical trials. This overview is based on (i) results reported in literature (via PubMed) or (ii) companies press releases and (iii) […]

Read the full article →

Trends in cord blood enhancement 2013

November 10, 2013

I’m following with a big interest the latest development in technologies for cord blood (CB) enhancement in hematology. “Enhancement” means boosting a therapeutic value of cord blood graft via its stimulation/ modification (homing, migration, engraftment) or increase cell number (expansion, processing optimization). Today, I’m going to overview very recent trends and give update on methodologies […]

Read the full article →

Hurdles in conducting of cell therapy trials for acute neurological conditions

October 20, 2013

Acute neurological conditions, such as stroke and traumatic brain injury (TBI) is an attractive target for cell therapy. Success of pre-clinical models allowed to move to clinical trials relatively quickly. Industry also sees a great opportunity in this direction. For example, Athersys and Cytomedix have active ongoing Phase 2 trials. However, the trials did not […]

Read the full article →

Failure of autologous cord blood transplant in diabetes

October 13, 2013

I’ve written about trials, assessing autologous cord blood transplantation (CBT) in pediatric type 1 diabetes. The results of first such trial, conducted by University of Florida in collaboration with NIH, were disappointing. The results of another trial, conducted in Germany and utilized the same protocol, have been published very recently. And as US trial, this […]

Read the full article →

Grafix – a hype or revolution in medicine?

August 17, 2013

A new press release of US-based Osiris Therapeutics boost a value of the company more than twice overnight. The price per share skyrocketed from $10 to $25 (+140%) in a single day – August 13. This is a very rare case for cell therapy industry and it made me wonder – why did it happen? […]

Read the full article →

Stem cell therapy in multiple sclerosis – no immune re-installation

August 4, 2013

Stem cell-based therapy of multiple sclerosis (MS) is a very hot topic. There are a lot of clinical trials going on right now all around the world. Considerably, MS is autoimmune disease, where auto-reactive T-cells enter central nervous system and attack myelin. This auto-aggression leads to inflammation and, eventually, to neurodegeneration. Pathogenesis-based concept behind of […]

Read the full article →

Flaws and errors in cardiac cell therapy reporting – Interview with Darrel Francis

July 22, 2013

Darrel Francis – Professor of Cardiology at the Imperial College London. He is a senior author of the recent report, which challenges the validity of research and clinical trials in cardiac cell therapy, conducted by Bodo-Eckehard Strauer’s group. He kindly agreed to answer my questions. 1. Dr. Francis, What is your interest in cardiac cell […]

Read the full article →